Mild-to-Moderate Mitral Regurgitation and Flecainide Use
Mild-to-moderate mitral regurgitation without heart failure is NOT a contraindication to flecainide use, as this degree of valvular disease does not constitute the "structural heart disease" referenced in guidelines.
Understanding "Structural Heart Disease" in Flecainide Guidelines
The contraindication to flecainide specifically refers to ischemic heart disease and heart failure with reduced ejection fraction, not mild valvular abnormalities 1. The ACC/AHA/HRS guidelines explicitly state that flecainide and propafenone are contraindicated in patients with "structural heart disease or ischemic heart disease," but this terminology has been clarified to mean:
- Post-myocardial infarction patients (as in the CAST trial) 1, 2
- Heart failure with reduced ejection fraction (LVEF <40%) 2
- Severe left ventricular hypertrophy 3
- Active coronary artery disease with ischemia 1
Why Mild-Moderate MR is Different
Mild-to-moderate mitral regurgitation without associated left ventricular dysfunction does not fall into the high-risk category for flecainide-induced proarrhythmia 1. The FDA label warns about heart failure and cardiogenic shock as contraindications, but does not list isolated valvular disease 2.
Key distinctions:
- The CAST trial that established flecainide's mortality risk studied post-MI patients with ventricular arrhythmias and reduced ejection fraction—not patients with valvular disease 2
- Recent evidence suggests flecainide safety has been overgeneralized, and it may be safe in various structural conditions when ventricular function is preserved 4, 5
- Guidelines recommend flecainide for supraventricular arrhythmias in patients "without structural heart disease," which operationally means preserved LV function and no ischemic disease 1
Clinical Application
You can use flecainide in this patient if:
- No clinical heart failure (as stated in your question) 1, 2
- Preserved left ventricular ejection fraction (>40%) 3, 2
- No coronary artery disease or active ischemia 1
- No severe left ventricular hypertrophy 3
Monitor for:
- Development of heart failure symptoms, as flecainide has negative inotropic effects 2
- Conduction abnormalities (PR prolongation, QRS widening) 2
- Plasma levels if available, keeping trough levels <0.7-1.0 mcg/mL 2
Important Caveats
The 2024 ESC AF guidelines continue to recommend flecainide for rhythm control in patients without "impaired left ventricular systolic function, severe left ventricular hypertrophy, or coronary artery disease" 3. This reinforces that functional capacity of the left ventricle, not the presence of mild valvular disease, determines safety.
Recent observational data from 2025 showed no increased ventricular arrhythmias in patients with structural heart disease (including those with LVH and mild LV dysfunction) compared to those without, though this requires prospective validation 5.
The key safety principle: Flecainide's proarrhythmic risk is primarily in patients with ischemic substrates and reduced contractility, not in those with isolated mild-moderate valvular regurgitation and preserved ventricular function 4, 6, 7.